Efficacy of tiotropium in COPD patients with FEV 1 ≥ 60 participating in the UPLIFT® trial

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 9, Issue 3, 2012, Pages 289-296

  Tashkin, Donald P ^a   Celli, Bartolome R ^b   Decramer, Marc ^c   Lystig, Theodore ^d   Liu, Dacheng ^d   Kesten, Steven ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Bbronchodilator agents; Chronic obstructive pulmonary disease; Eexacerbations.; Ppulmonary function tests; Qquality of life

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; LONG ACTING BETA 2 AGONIST; PLACEBO; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ADULT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HAZARD RATIO; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; SGRQ SCORE; SPIROMETRY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; BRONCHODILATOR AGENTS; COHORT STUDIES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SCOPOLAMINE DERIVATIVES; SPIROMETRY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84862072131     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2012.656211     Document Type: Review

References (24)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available from: http://www.goldcopd.org/Guidelineitem. asp?l1=2&l2=1&intId=2003. Updated 2009.
2. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP; on behalf of the UPLIFTR study investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): A prespecifi ed subgroup analysis of a randomised controlled trial. Lancet 2009; 374:1171-1178.
3. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J. Effi cacy of salmeterol/fl uticasone propionate by GOLD stage of chronic obstructive pulmonary disease; analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10:59.
4. Wilt TJ, Niewoehner D, MacDonald R, Kane RL. Management of stable chronic obstructive pulmonary disease: A systematic review for a clinical practice guideline. Ann Intern Med 2007; 147:639-653.
5. Enright P. Don't prescribe tiotropium for smokers with an FEV1 above 60% predicted. Prim Care Respir J 2009; 18:119-120.
6. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators. A four-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359:1543-1554.
7. McGarvey LP, Magder S, Burkhart D, Kesten S, Liu D, Manuel RC, Niewoehner DE. Cause-specific mortality adjudication in the UPLFIT copd trial: Findings and recommendations. Respir Med 2011 [Epub ahead of print].
8. Tashkin DP, Celli B, Kesten S, Lystig T, Mehra S, Decramer M. Long-term effi cacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J 2009; 103:963-974.
9. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH investigators. Salmeterol and fl uticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-789.
10. Johansson G, Lindberg A, Romber K, Nordstrom L, Gerken F, Roquet A. Bronchodilator effi acy of tiotropium in patients with mild to moderate copd. Prim Care Respir J 2008; 17:169-175.
11. Mahler DA, Harver A. A factor analysis of dyspnea ratings, respiratory muscle strength, and lung function in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 145(2 Pt 1):467-470.
12. Jones PW. Issues concerning health-related quality of life in copd. Chest 1995(May Supplement); 107:187s-193s.
13. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Th orax 2001; 56:880-887.
14. Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, Perez T, Soler-Cataluna JJ, van der Molen T, Adamek L, Banik N. Health-related quality of life in patients by copd severity within primary care in Europe. Respir Med 2011; 105:57-66.
15. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinfl ation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:770-777.
16. Cooper CB. Airfl ow obstruction and exercise. Respir Med 2009; 103:325-334.
17. Babb TG, Viggiano R, Hurley B, Staats B, Rodarte JR. Effect of mild-to-moderate airfl ow limitation on exercise capacity. J Appl Physiol 1991; 70:223-230.
18. O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H. Eff ects of tiotropium on lung hyperinfl ation, dyspnoea and exercise tolerance in copd. Eur Respir J 2004; 23:832-840.
19. O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004; 24:86-94.
20. Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba FC, Richter K, Kesten S, O'Donnell D. Improvements in symptomlimited exercise performance overy 8 h with once-daily tiotropium in patients with copd. Chest 2005; 128:1168-78.
21. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA; Evaluation of copd Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363:1128-1138.
22. Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and effi cacy of combined long-acting β-agonists and inhaled corticosteroids vs long-acting β-agonists monotherapy for stable copd. Chest 2009; 136:1029-1038.
23. Rodrigo GJ, Nannini LJ. Tiotropium for the treatment of stable chronic obstructive pulmonary disease: A systematic review with meta-analysis. Pulm Pharmacol Ther 2007; 20:495-502.
24. Baker WL, Baker EL, Coleman CI. Pharmacologic treatments for chronic obstructive pulmonary disease: A mixed-treatment comparisons meta-analysis. Pharmacotherapy 2009: 29:891-905.